Medindia LOGIN REGISTER
Medindia
Advertisement

New Treatment Offers Hope For Advanced Prostate Cancer

by Kanimozhi Tamilselvan on October 5, 2017 at 10:26 AM
New Treatment Offers Hope For Advanced Prostate Cancer

A new treatment offers hope for advanced-stage, metastatic castration-resistant prostate cancer (mCRPC). Therapy options are limited for men with advanced prostate cancer.

In the featured article of The Journal of Nuclear Medicine's, German researchers report on their recent clinical experience, which establishes a dosing regimen for actinium-225 (225Ac)-labeled targeted alpha therapy of patients with prostate-specific membrane antigen (PSMA)-positive tumors.

Advertisement


The protocol balances treatment response with toxicity concerns to provide the most effective therapy with the least side effects.

"The idea of targeted alpha therapy is not completely novel," explains Clemens Kratochwil, MD, University Hospital Heidelberg in Germany. "However, in contrast to hundreds of preclinical research reports, the clinical experience is still very limited. Our current results present a milestone about clinical translation because we could demonstrate how preclinical knowledge can be applied to human beings."
Advertisement

Salvage therapy results show treatment with 100kBq/kg 225Ac-PSMA-617 is tolerated by patients and demonstrates a promising anti-tumor response. Also, it was determined that repeated treatments at intervals of eight weeks might lead to continuing tumor control.

"We developed a treatment protocol that presents a promising trade-off between toxicity and anti-tumor activity of PSMA-directed targeted alpha therapy," says Kratochwil.

"However, our current results present only a starting-dose that, on the one hand, has still to be optimized and, on the other hand, needs further studies to evaluate its efficacy. Ultimately, there could be a new treatment modality to improve symptomatic patients and prolong survival."

Looking ahead, Kratochwil states, "If PSMA-targeted alpha therapy keeps its promise, it may earn a significant place in therapeutic nuclear medicine. However, it is the nature of all molecular targeting therapies that they can only be useful if the target is sufficiently expressed in the tumors.

Thus, molecular imaging using PSMA-PET/CT also has an important role as a stratification criterion, and the 'theranostic' concept [combining diagnostic imaging of a biomarker with precise therapy] may be an additional motivation to establish PSMA-PET/CT as a routinely available imaging modality."

Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Cancer News

New Therapy for Biliary Tract Cancer
The effects and mechanisms of microRNA-451a (miR-451a), which hinders the progression of gemcitabine-resistant biliary tract cancers, are under study.
Blood Test for Early Detection of Pancreatic Cancer
The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.
Nutrients in Beef and Dairy Promote Cancer Immunotherapy
A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.
Combination Therapy Holds Promise for Brain Tumor in Children
Trametinib plus dabrafenib combined therapy demonstrated a clear therapeutic benefit in children with BRAF-mutated low- and high-grade gliomas.
Urban Environments Fuel Higher Breast Cancer Rates
Examining breast cancer occurrence and stages reveals disparities in urban versus rural rates, influenced by environmental conditions and the stage of the disease.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

New Treatment Offers Hope For Advanced Prostate Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests